EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Concentration–QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval

Jesper Sundell iD, Dinko Rekic iD, Johanna Melin iD, Susanne Johansson iD, Ahmad Ebrahimi iD, Corina Dota, Joanna Parkinson iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.13272 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Jesper Sundell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Swed…. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Long QT Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Balcinrenone (AZD9977) is a selective mineralocorticoid receptor modulator in development in combination with dapagliflozin for treatment of heart failure with impaired kidney function and chronic kidney disease. A prespecified concentration–QT analysis was performed based on data from a phase I single ascending dose study prospectively designed as a thorough QT study substitute. Oral single doses of balcinrenone of 5–800 mg, plus fractionated doses of 800 and 1200 mg, were evaluated in 62 healthy male participants. Time‐matched 12‐lead digital electrocardiogram and plasma concentrations were measured pre‐dose and up to 48 h postdose in the participants. Analysis was performed using a linear mixed‐effect model, where baseline‐adjusted Fridericia‐corrected QT interval (ΔQTcF) was a dependent variable and time‐matched balcinrenone concentration an independent variable. The model fit was deemed adequate by evaluation of goodness‐of‐fit plots, and the slope of the concentration–ΔQTcF relationship was nonsignificant (−0.003 ms/μmol/L; 95% confidence interval [CI]: −0.181, 0.176). The high clinical exposure scenario was defined as the maximum concentration (2.156 μmol/L) following the highest expected therapeutic dose (40 mg once daily) under fed conditions and in presence of a strong cytochrome P450 3A4 inhibitor. Estimated baseline‐adjusted and placebo‐corrected QTcF interval (ΔΔQTcF) at this concentration was 0.35 ms (90% CI: −1.29, 2.00). Furthermore, the upper 90% ΔΔQTcF CI was estimated to be below the threshold of regulatory concern of 10 ms at all observed concentrations (up to 16.7 μmol/L). Hence, it can be concluded that balcinrenone does not induce QTcF prolongation at the high clinical exposure scenario.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mineralocorticoid Receptor AntagonistsLong QT SyndromeHumansMaleAdultElectrocardiographyYoung AdultDose-Response Relationship, DrugMiddle AgedHealthy VolunteersModels, Biological

Substanzen

Mineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Lund University, Lund, Sweden.
  • Alexion, AstraZeneca, Rare Disease, Boston, Massachusetts, USA.
  • Cardiovascular Safety Center of Excellence and SKGs, Global Patient Safety, Oncology R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Jesper Sundell, Dinko Rekic, Johanna Melin, Susanne Johansson, Ahmad Ebrahimi, Joanna Parkinson

Förderung

  • AstraZeneca

Zitieren

APA

Sundell, J., Rekic, D., Melin, J., Johansson, S., Ebrahimi, A., Dota, C., & Parkinson, J. (2025). Concentration–QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13272

Vancouver

Sundell J, Rekic D, Melin J, Johansson S, Ebrahimi A, Dota C, et al. Concentration–QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13272

BibTeX
@article{Sundell2025,
  author = {Sundell, Jesper and Rekic, Dinko and Melin, Johanna and Johansson, Susanne and Ebrahimi, Ahmad and Dota, Corina and Parkinson, Joanna},
  title = {Concentration–QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.13272}
}
Kostenlos starten →